Vyome Unveils Preclinical Data For VT-1908 Eye Drops To Treat Uveitis, A Leading Cause Of Blindness

Vyome Holdings, Inc. (NASDAQ:HIND), a clinical-stage healthcare holding company, presented results from its preclinical studies investigating VT-1908 (the first topical formulation of mycophenolate) for treating uveitis at the recent Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics (1).

Uveitis is the inflammation of a part of the eye, and is implicated in 30,000 new cases of legal blindness annually, in the United States alone (2), making it a roughly $3B market opportunity by 2032. Steroids are the first line of treatment for uveitis, but many patients do not respond, and steroid use causes major complications, including cataract and increased pressure in the eye, leading to glaucoma. There is a huge unmet need for a topically administered drug to replace steroid use in the eye. Vyome is developing VT-1908 to address this major unmet need. The broader addressable global market to treat inflammation in the eye is expected to exceed $20B by 2030 (5).

In a preclinical model of anterior uveitis, the most common form of uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score. The efficacy of VT-1908 was found to be similar to a clinically used steroid (1).